500 patients67,039 observations150 daysLIVE

Patient P-03267

Synthetic patientONX-7 · Day 149 · 55–64 · M · baseline S05Open companion preview
Therapy response
Declining
Tolerance
Improving
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
49%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S05
  2. Day 99 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 99.

Primary contributors, last 14 days
  • GI instability-10
  • Toxicity-6
  • Treatment adherence-3
  • Inflammatory activity-2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    57%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 83% showed improvement
    • median effect visible after 8 days

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 60
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 48 and rising
      • WearableSleep 5.3 h, below personal baseline
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 28/100
      • Daily logFibre intake low in recent food logs
    • Drug metabolism and exposure 55
      • DNADPYD *2A → slower clearance
      • BloodToxicity index 47
    • Inflammatory signalling 45
      • MicrobiomeBacteroides fragilis expansion
      • BloodInflammatory load index 54
    • Autonomic recovery 45
      • WearableResting HR 84 bpm
      • WearableShort sleep window
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • DPYD *2A heterozygous
      Slower drug clearance
    • CYP2D6 Normal metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 2.2 · butyrate capacity 28/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisHigh
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    39 ms
    Sleep
    5.2 h
    Steps
    4,045
    Resting HR
    85 bpm
    Daily log: GI score 48, nutritional resilience 42, adherence 65.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Protect a 7.5-hour sleep window; screens off 30 minutes before
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0335248%S1959
    P-0344447%S1762
    P-0304646%S20GI-04no change53
    P-0316646%S20CR-01improved62
    P-0326046%S1954
    P-0346544%S17CR-01improved65
    P-0327143%S1966
    P-0316442%S1158
    P-0338442%S0155
    P-0335741%S02CR-01improved50
    P-0312340%S14GI-04improved50
    P-0315139%S1851